Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

CAR-T cells manufactured after multiple myeloma triplet or quadruplet induction therapy have reduced functionality and an altered composition

View Full Paper
Ask AI
Bookmark
Share

Authors

ZWZachary J. WalkerMKM. Eric Kohler

Discussion

Loading...

Member takes

Overview

Findings reveal reduced cytotoxicity and altered CD4/CD8 ratios in CAR-T cells after anti-MM treatment, suggesting effects on cancer therapy outcomes.

Key Points

  • This research aims to investigate the impact of frontline anti-multiple myeloma treatment on the efficacy of CAR-T cells.
  • Generated CAR-T cells from blood samples of MM patients at various treatment stages.
  • Assessed CAR-T cell characteristics including CD4/CD8 ratios and cytotoxicity against H929 cells.
  • Evaluated manufacturing efficiency and phenotypic changes in CAR-T cells post-treatment.
  • Post-induction CAR-T cells showed reduced cytotoxicity against H929 cells compared to newly diagnosed CAR-T cells.
  • CD4/CD8 ratios were significantly lower in post-induction CAR-T cells than in those from newly diagnosed patients.
  • Increased expression of inhibitory receptors TIGIT and PD-1 was observed in post-induction CAR-T cells.

Cite This Study

Walker et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d6d6https://doi.org/10.1182/blood-2025-5725
View Full Paper
Ask AI
Bookmark
Share